trial

The Effect of Ketamine on Attentiveness

NCTId NCT01165294
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2009-10
Primary completion
—
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Ketamine

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
24
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
Ketamine
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizophrenia
indication